Observational studyFrontiers in immunology2026
Levels of myeloid-derived suppressor cell-like cells in early sepsis: a comparative study with non-septic patients.
Observational study in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Myeloid-derived suppressor cells (MDSCs) are immature myeloid cells with immunosuppressive functions. While early expansion of MDSCs may be protective in various pathological states, their accumulation and role might differ in sepsis. This study aimed to compare the differences in circulating myeloid cells with MDSC phenotypes and their subsets between septic and non-septic patients in the early stage. Methods: This was a prospective, single-center, observational cohort study. Critically ill patients were enrolled and divided into sepsis and non-sepsis groups. Flow cytometry was used to determine the percentages of peripheral blood CD11b Results: Sixty patients were enrolled (sepsis group: n=38; non-sepsis group: n=22). No significant differences were found in gender, age, APACHE II score, ICU length of stay, or 28-day mortality between the two groups. However, the Charlson Comorbidity Index (CCI) was higher in the sepsis group (P = 0.005). Compared to the non-sepsis group, septic patients had significantly lower percentages of total MDSC-like cells and M-MDSC-like cells (P = 0.006; P = 0.003), while PMN-MDSC-like cells showed no difference. ARG-1 levels were higher in the sepsis group (P = 0.030). Furthermore, the sepsis group exhibited significantly elevated levels of IL-6, CRP, PCT, and SOFA scores (P<0.05), lower lymphocyte counts (P = 0.017), and more pronounced coagulation abnormalities, hypoalbuminemia, and increased cardiac/renal markers. Within the sepsis group, non-survivors had a significantly higher percentage of PMN-MDSC-like cells than survivors (P = 0.012). Conclusion: In the early stage, septic patients exhibit a distinct response profile of myeloid cells with MDSC phenotypes compared to non-septic patients, characterized by attenuated expansion of total MDSC-like cells and M-MDSC-like cells but enhanced ARG-1 expression, alongside more severe inflammation, organ dysfunction, and lymphopenia. An elevated percentage of PMN-MDSC-like cells is associated with poor prognosis in sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.